Antidote Therapeutics, Inc.

Antidote Therapeutics is a biopharmaceutical company developing nicotine-blocking therapeutic candidates to treat diseases caused by nicotine, including rare vascular diseases and addiction. The company's pipeline includes ATI-1013, a fully human anti-nicotine monoclonal antibody in development, and ATI-3009, a nicotine-degrading enzyme in lead optimization.